By Sabela Ojea
Acadia Pharmaceuticals said it is selling its rare pediatric disease priority review voucher for $150 million.
The biotechnology company on Tuesday said it plans to invest the proceeds from the sale toward research and development programs in central nervous system and rare diseases.
The company didn't reveal the name of the buyer.
Acadia Pharmaceuticals said the definitive asset purchase agreement came after it was granted the priority review voucher in March 2023 following the Food and Drug Administration approval of Daybue for the treatment of Rett syndrome.
Daybue was initially licensed by Acadia from Neuren Pharmaceuticals Limited in August 2018, so Acadia is required to pay Neuren one-third of the net proceeds, it said.
Rett syndrome is a genetic disorder that affects the nervous system.
Write to Sabela Ojea at sabela.ojea@wsj.com
(END) Dow Jones Newswires
November 05, 2024 17:19 ET (22:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。